1. A vaccine containing at least one peptide consisting of the amino acid sequence LRANISHKDMQLGR (SEQ ID No. 1), or a fragment of this peptide, conjugated or fused to a carrier protein containing at least one T-cell epitope, and this peptide the fragment contains at least 7 amino acid residues and the amino acid sequence KDMQLGR (SEQ ID No: 7) or KDMQLG (SEQ ID No: 23), provided that the peptide fragment does not consist of the amino acid sequences HKDMQLGR (SEQ ID No: 16) and HKDMQLG ( SEQ ID No: 22) .2. A vaccine according to claim 1, characterized in that the peptide fragment comprises the amino acid sequence KDMQLGR (SEQ ID No: 7). The vaccine according to claim 1, characterized in that the peptide fragment is selected from the group consisting of RANISHKDMQLGR (SEQ ID No. 2), ANISHKDMQLGR (SEQ ID No. 3), NISHKDMQLGR (SEQ ID No. 4), ISHKDMQLGR (SEQ ID No. .5), SHKDMQLGR (SEQ ID No. 6), KDMQLGR (SEQ ID No. 7), LRANISHKDMQLG (SEQ ID No. 8), RANISHKDMQLG (SEQ ID No. 9), ANISHKDMQLG (SEQ ID No. 10), NISHKDMQLG (SEQ ID No. 11), ISHKDMQLG (SEQ ID No. 12) and SHKDMQLG (SEQ ID No. 13). 4. The vaccine according to claim 1, characterized in that the LRANISHKDMQLGR peptide fragment (SEQ ID No. 1) containing KDMQLGR (SEQ ID No. 7) is selected from the group consisting of RANISHKDMQLGR (SEQ ID No. 2), ANISHKDMQLGR (SEQ ID No. 3), NISHKDMQLGR (SEQ ID No. 4), ISHKDMQLGR (SEQ ID No. 5), SHKDMQLGR (SEQ ID No. 6), KDMQLGR (SEQ ID No. 7) .5. A vaccine according to claim 1, characterized in that at least one peptide consisting of the amino acid sequence LRANISHKDMQLGR (SEQ ID No. 1), or its peptide fragment, contains at least one cysteine residue directly associated with it at its N-terminus or through a spacer sequence. 6. A vaccine according to claim 1, characterized in that the carrier is a protein carrier. The vaccine according to claim 6, characterized in that the protein carrier is selected from the group consisting of mollusk hemocyanin saucer (KLH), tetanus toxoid (TT)1. В
